SCHEMBL25834788

SCHEMBL25834788

CCCCC/C=C\C/C=C\C/C=C\CCCCCCC(=O)C(C)C

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.67
PPARG P37231 5/20 0.67
F7 P08709 4/20 0.67
F3 P13726 4/20 0.67
KDM4E B2RXH2 4/20 0.67
PPARD Q03181 4/20 0.67
PPARA Q07869 4/20 0.67
FABP3 P05413 3/20 0.67
FFAR1 O14842 3/20 0.67
PTGS1 P23219 2/20 0.67
LMNA P02545 2/20 0.67
CYP3A4 P08684 2/20 0.67
CYP19A1 P11511 2/20 0.67
FABP4 P15090 2/20 0.67
HPGD P15428 2/20 0.67
ALOX15 P16050 2/20 0.67
NR4A2 P43354 2/20 0.67
HSD17B10 Q99714 2/20 0.67
TDP1 Q9NUW8 2/20 0.67
DUSP3 P51452 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20074366 1.00 ALDH1A1 (0.67) ALDH1A1PPARGF7F3KDM4E
SCHEMBL23950453 1.00 ALDH1A1 (0.67) ALDH1A1PPARGF7F3KDM4E
SCHEMBL21448748 1.00 ALDH1A1 (0.67) ALDH1A1PPARGF7F3KDM4E
SCHEMBL11892066 1.00 ALDH1A1 (0.67) ALDH1A1PPARGF7F3KDM4E
SCHEMBL21147476 0.98 PPARG (0.66) ALDH1A1PPARGF7F3KDM4E
SCHEMBL23950505 0.97 ALDH1A1 (0.64) ALDH1A1PPARGF7F3KDM4E
SCHEMBL23950452 0.95 TERT (0.63) PPARGF7F3PPARDPPARA
SCHEMBL23950440 0.95 TERT (0.63) PPARGF7F3PPARDPPARA
SCHEMBL23950153 0.95 TERT (0.63) PPARGF7F3PPARDPPARA
SCHEMBL21448814 0.95 TERT (0.63) PPARGF7F3PPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 US disclosed
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS CPT1B, MUSK, MYLK2 ALDH1A1 1330/4885PPARG 271/4885F7 4629/4885
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 ALDH1A1 2528/4885PPARG 498/4885F7 3177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.